



F.No. 1-2/2020-CEO(DRAP)  
Government of Pakistan  
**(Drug Regulatory Authority of Pakistan)**  
T.F Complex, 7<sup>th</sup> Mauve Area G-9/4, Islamabad..  
\*\*\*\*\*

**Tele:** +9251-9107316  
**Fax:** +9251-9107318


Islamabad, the 27<sup>th</sup> March 2020

**ADVISORY**

**Subject: ENSURING PRESCRIPTION-BASED SALE OF HYDROXYCHLOROQUINE AND AZITHROMYCIN CONTAINING DOSAGE FORMS.**

In continuation and addition with earlier correspondence dated 20<sup>th</sup> March, 2020, on the subject matter, under the current situation of SARS-CoV-2 (COVID-19) pandemic, it has been observed that few elements are also hoarding the stocks of certain drugs including Azithromycin (capsules and suspension) and Hydroxychloroquine (tablets). This is against Islamic and ethical principles. Availability of all medicines is to be ensured throughout the country specially Hydroxychloroquine and Azithromycin containing dosage forms by taking following measures:

- a. Azithromycin (capsules and suspension) and Hydroxychloroquine (tablets) shall be sold at the licensed pharmacies, drug/ medical stores only on prescription basis.
  - b. All licensed sale points shall maintain record of the prescriptions of a registered physician/ consultant for Azithromycin and Hydroxychloroquine on which this drug is sold."
2. Provincial drug control administrations are requested to take necessary steps for ensuring abovementioned measure.
  3. This issue on the directions of CEO, DRAP.

  
27/03/2020  
(Sayyad Hussain Khan)  
**Deputy Director to  
Chief Executive Officer**

**Distribution:**

1. Chief Drug Controller, Punjab
2. Chief Drug Controller, GB
3. Chief Drug Inspectors, KP
4. Chief Drug Inspector, Sindh
5. Chief Drug Inspector, Baluchistan
6. Senior Drug Inspector, ICT
7. Additional Director, QA & LT, Islamabad